Bluebird Bio

#Bluebird Bio #Cell and gene therapy #Gene therapy #Genetic diseases #Mergers and acquisitions

New DDW Highlights podcast: 4 March 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. It’s been a mixed bag of news for gene therapies this week, ranging from… Read More

#News

#Bluebird Bio #Cell and gene therapy #Gene therapy #Genetic diseases #Mergers and acquisitions

This week in drug discovery (24-28 February) 

News round-up for 23-28 February by DDW Senior Digital Content Editor Diana Spencer. It’s been a mixed bag of news for gene therapies this week, ranging from huge successes in treating sight impairment, cystic fibrosis and hearing loss, to the quick sale of a previously successful gene therapy… Read More

#News

FDA
#Bluebird Bio #Cell and gene therapy #CRISPR #CRISPR Therapeutics #FDA #Sickle cell disorder (SCD) #Vertex

FDA approves gene therapies for sickle cell disease (with a warning)

The US Food and Drug Administration (FDA) has approved the first cell-based gene therapies for the treatment of sickle cell disease (SCD), Casgevy and Lyfgenia. Casgevy, from Vertex Pharmaceuticals and CRISPR Therapeutics, is also the first FDA-approved treatment to use CRISPR gene editing technology. However, the FDA added a black… Read More

#News #Regulatory #Trending News